Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Nadifloxacin

Fluoroquinolone antibacterial agent
 
ALX-380-294-M250 250 mg 112.00 USD
 
ALX-380-294-G001 1 g 325.00 USD
Do you need bulk/larger quantities?
 
Fluoroquinolone with broad spectrum activity against Gram-negative and Gram-positive bacteria. Inhibits the generation of O2- and OH radicals by neutrophils. Inhibits the production of inflammatory cytokines.

Product Specification

Alternative Name:9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid, Jinofloxacin, OPC-7251
 
Formula:C19H21FN2O4
 
MW:360.4
 
CAS:124858-35-1
 
MI:14: 6345
 
Purity:≥98% (Assay)
 
Identity:Determined by IR.
 
Appearance:White to yellow crystalline solid.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
380-294
Please mouse over
380-294

Product Literature References

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771: M.R. Jacobs & P.C. Appelbaum; Expert Opin. Pharmacother. 7, 1957 (2006), Abstract;
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes: K. Kuwahara, et al.; J. Dermatol. Sci. 38, 47 (2005), Abstract;
Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections: P. Nenoff, et al.; Chemotherapy 50, 196 (2004), Abstract;
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus: N. Oizumi, et al.; J. Infect. Chemother. 7, 191 (2001), Abstract;
Effect of nadifloxacin on neutrophil functions: H. Akamatsu, et al.; J. Int. Med. Res. 23, 19 (1995), Abstract;
Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris: K. Vogt, et al.; Eur. J. Clin. Microbiol. Infect. Dis. 11, 943 (1992), Abstract;
Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base: I. Kurokawa, et al.; J. Am. Acad. Dermatol. 25, 674 (1991), Abstract;
Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids: H. Ishikawa, et al.; Chem. Pharm. Bull. 37, 2103 (1989), Abstract;

Product Toolbox

PRODUCT RESOURCES

Print as PDF
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
DNA gyrase
By biological activity:
DNA gyrase Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,